Last reviewed · How we verify
Switch to DTG + 3TC
DTG (dolutegravir) inhibits HIV integrase to prevent viral DNA integration into the host genome, while 3TC (lamivudine) inhibits reverse transcriptase to block HIV replication.
DTG (dolutegravir) inhibits HIV integrase to prevent viral DNA integration into the host genome, while 3TC (lamivudine) inhibits reverse transcriptase to block HIV replication. Used for HIV-1 infection in treatment-experienced or treatment-naive adults, HIV-1 infection as part of combination antiretroviral therapy.
At a glance
| Generic name | Switch to DTG + 3TC |
|---|---|
| Sponsor | Hospitales Universitarios Virgen del Rocío |
| Drug class | Antiretroviral combination (INSTI + NRTI) |
| Target | HIV integrase; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the enzyme responsible for inserting HIV DNA into human chromosomes, preventing viral replication at a critical step. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that terminates HIV RNA-dependent DNA synthesis. Together, this dual-agent combination provides potent antiretroviral activity with a high genetic barrier to resistance.
Approved indications
- HIV-1 infection in treatment-experienced or treatment-naive adults
- HIV-1 infection as part of combination antiretroviral therapy
Common side effects
- Insomnia
- Headache
- Diarrhea
- Nausea
- Fatigue
- Rash
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa (NA)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- POC HIV Testing and Early DTG Use for Infants (PHASE4)
- A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Switch to DTG + 3TC CI brief — competitive landscape report
- Switch to DTG + 3TC updates RSS · CI watch RSS
- Hospitales Universitarios Virgen del Rocío portfolio CI